Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results at 2023 AHA Hypertension Scientific Sessions

Mineralys Therapeutics, Inc. presented final results from the Target-HTN Phase 2 trial of lorundrostat at the 2023 American Heart Association (AHA) Hypertension Scientific Sessions, and simultaneously published in the Journal of the American Medical Association (JAMA).

Related Keywords

United States ,Boston ,Massachusetts ,American ,Luke Laffin ,Jon Congleton ,American Heart Association ,Mineralys Therapeutics Inc ,Journal Of The American Medical Association ,Vascular Thoracic Institute At Cleveland Clinic ,Mineralys Therapeutics ,Heart Association ,Hypertension Scientific Sessions ,Synthase Inhibition ,Uncontrolled Hypertension ,Clinical Trial ,American Medical Association ,Chief Executive Officer ,Blood Pressure Disorders ,Thoracic Institute ,